Article Abstract:
Belmac Corp's respiratory tract infection treatment drug Biolid captured 4.2% of the market for macrolide antibiotics in France during its first 60 marketing days. Belmac obtained patent for the drug in Sep 1991 and granted license to Bristol-Myers Squibb Co to market it as the drug Odocine in 26 nations. The firm is also developing the drugs Phenantramine, a cure for malaria, and Azaquinone, for tuberculosis and AIDS-related mycobacterium avium complex. Belmac registered a loss of $4.8 million during the first nine months ending in March of FY 1992 on sales of $8.6 million of its newly-acquired Chimos S.A.
User Contributions:
Comment about this article or add new information about this topic:
Article Abstract:
Marion Merrell Dow Pres and CEO Fred Lyons bought 12,400 shares of the Kansas City pharmaceutical firm. The firm's three product lines showed strong sales records for the 2nd qtr and 1st half ended Jun 1992. The Cardizem drugs posted a 15% 1st half sales advance to $464 million. The Seldane anti-allergy drugs showed a 31% 1st half sales increase to $501 million. Nicoderm transdermal patch Jun 1992 qtr sales rose to $82 million. The company's stock, however, is selling at a 30% discount because of the anticipation of stiff competition when its patent on the Cardizem product expires.
User Contributions:
Comment about this article or add new information about this topic:
Article Abstract:
BARR Laboratories Inc Chmn and controlling stockholder Dr. Bernard Sherman, has purchased 250,000 shares at 8 3/4 despite the Food and Drug Administration's (FDA) clampdown on the company's failure to suspend manufacturing and distribution of products under regulatory disputes. In a countersuit in Federal District Court, BARR has claimed that the FDA action was used to exclude the company from new generic drug applications.
User Contributions:
Comment about this article or add new information about this topic: